ADVERSE O
REACTIONS O
Associated O
with O
Discontinuation O
of O
Treatment O
Approximately O
16 O
% O
of O
the O
453 O
patients O
who O
received O
REMERON O
( O
mirtazapine O
) O
Tablets O
in O
US O
6-week O
controlled O
clinical O
trials O
discontinued O
treatment O
due O
to O
an O
adverse O
experience O
, O
compared O
to O
7 O
% O
of O
the O
361 O
placebo-treated O
patients O
in O
those O
studies O
. O

The O
most O
common O
events O
( O
> O
=1 O
% O
) O
associated O
with O
discontinuation O
and O
considered O
to O
be O
drug O
related O
( O
i.e. O
, O
those O
events O
associated O
with O
dropout O
at O
a O
rate O
at O
least O
twice O
that O
of O
placebo O
) O
are O
included O
in O
Table O
2 O
. O

Table O
2 O
: O
Common O
Adverse O
Events O
Associated O
With O
Discontinuation O
of O
Treatment O
in O
6-Week O
US O
REMERON O
Trials O
Adverse O
Event O
Percentage O
of O
Patients O
Discontinuing O
With O
Adverse O
Event O
REMERON O
( O
n=453 O
) O
Placebo O
( O
n=361 O
) O
Somnolence B-OSE_Labeled_AE
10.4 O
% O
2.2 O
% O
Nausea B-OSE_Labeled_AE
1.5 O
% O
0 O
% O
Commonly O
Observed O
Adverse O
Events O
in O
US O
Controlled O
Clinical O
Trials O
The O
most O
commonly O
observed O
adverse O
events O
associated O
with O
the O
use O
of O
REMERON O
( O
mirtazapine O
) O
Tablets O
( O
incidence O
of O
5 O
% O
or O
greater O
) O
and O
not O
observed O
at O
an O
equivalent O
incidence O
among O
placebo-treated O
patients O
( O
REMERON O
incidence O
at O
least O
twice O
that O
for O
placebo O
) O
are O
listed O
in O
Table O
3 O
. O

Table O
3 O
: O
Common O
Treatment-Emergent O
Adverse O
Events O
Associated O
With O
the O
Use O
of O
REMERON O
in O
6-Week O
US O
Trials O
Adverse O
Event O
Percentage O
of O
Patients O
Reporting O
Adverse O
Event O
REMERON O
( O
n=453 O
) O
Placebo O
( O
n=361 O
) O
Somnolence B-OSE_Labeled_AE
54 O
% O
18 O
% O
Increased B-OSE_Labeled_AE
Appetite I-OSE_Labeled_AE
17 O
% O
2 O
% O
Weight B-OSE_Labeled_AE
Gain I-OSE_Labeled_AE
12 O
% O
2 O
% O
Dizziness B-OSE_Labeled_AE
7 O
% O
3 O
% O
Adverse O
Events O
Occurring O
at O
an O
Incidence O
of O
1 O
% O
or O
More O
Among O
REMERON-Treated O
Patients O
Table O
4 O
enumerates O
adverse O
events O
that O
occurred O
at O
an O
incidence O
of O
1 O
% O
or O
more O
, O
and O
were O
more O
frequent O
than O
in O
the O
placebo O
group O
, O
among O
REMERON O
( O
mirtazapine O
) O
Tablets-treated O
patients O
who O
participated O
in O
short-term O
US O
placebo-controlled O
trials O
in O
which O
patients O
were O
dosed O
in O
a O
range O
of O
5 O
to O
60 O
mg/day O
. O

This O
table O
shows O
the O
percentage O
of O
patients O
in O
each O
group O
who O
had O
at O
least O
1 O
episode O
of O
an O
event O
at O
some O
time O
during O
their O
treatment O
. O

Reported O
adverse O
events O
were O
classified O
using O
a O
standard O
COSTART-based O
dictionary O
terminology O
. O

The O
prescriber O
should O
be O
aware O
that O
these O
figures O
can O
not O
be O
used O
to O
predict O
the O
incidence O
of O
side O
effects O
in O
the O
course O
of O
usual O
medical O
practice O
where O
patient O
characteristics O
and O
other O
factors O
differ O
from O
those O
which O
prevailed O
in O
the O
clinical O
trials O
. O

Similarly O
, O
the O
cited O
frequencies O
can O
not O
be O
compared O
with O
figures O
obtained O
from O
other O
investigations O
involving O
different O
treatments O
, O
uses O
, O
and O
investigators O
. O

The O
cited O
figures O
, O
however O
, O
do O
provide O
the O
prescribing O
physician O
with O
some O
basis O
for O
estimating O
the O
relative O
contribution O
of O
drug O
and O
nondrug O
factors O
to O
the O
side-effect O
incidence O
rate O
in O
the O
population O
studied O
. O

Table O
4 O
: O
Incidence O
of O
Adverse O
Clinical O
ExperiencesEvents O
reported O
by O
at O
least O
1 O
% O
of O
patients O
treated O
with O
REMERON O
are O
included O
, O
except O
the O
following O
events O
, O
which O
had O
an O
incidence O
on O
placebo O
greater O
than O
or O
equal O
to O
REMERON O
: O
headache B-NonOSE_AE
, O
infection B-NonOSE_AE
, O
pain B-NonOSE_AE
, O
chest B-NonOSE_AE
pain I-NonOSE_AE
, O
palpitation B-NonOSE_AE
, O
tachycardia B-NonOSE_AE
, O
postural B-NonOSE_AE
hypotension I-NonOSE_AE
, O
nausea B-NonOSE_AE
, O
dyspepsia B-NonOSE_AE
, O
diarrhea B-NonOSE_AE
, O
flatulence B-NonOSE_AE
, O
insomnia B-NonOSE_AE
, O
nervousness B-NonOSE_AE
, O
libido B-NonOSE_AE
decreased I-NonOSE_AE
, O
hypertonia B-NonOSE_AE
, O
pharyngitis B-NonOSE_AE
, O
rhinitis B-NonOSE_AE
, O
sweating B-NonOSE_AE
, O
amblyopia B-NonOSE_AE
, O
tinnitus B-NonOSE_AE
, O
taste B-NonOSE_AE
perversion I-NonOSE_AE
. O

( O
> O
=1 O
% O
) O
in O
Short-Term O
US O
Controlled O
Studies O
Body O
System O
Adverse O
Clinical O
Experience O
REMERON O
( O
n=453 O
) O
Placebo O
( O
n=361 O
) O
Body B-NonOSE_AE
as I-NonOSE_AE
a I-NonOSE_AE
Whole I-NonOSE_AE
Asthenia B-OSE_Labeled_AE
8 O
% O
5 O
% O
Flu B-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
5 O
% O
3 O
% O
Back B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
2 O
% O
1 O
% O
Digestive B-NonOSE_AE
System I-NonOSE_AE
Dry B-OSE_Labeled_AE
Mouth I-OSE_Labeled_AE
25 O
% O
15 O
% O
Increased B-OSE_Labeled_AE
Appetite I-OSE_Labeled_AE
17 O
% O
2 O
% O
Constipation B-OSE_Labeled_AE
13 O
% O
7 O
% O
Metabolic B-NonOSE_AE
and I-NonOSE_AE
Nutritional I-NonOSE_AE
Disorders I-NonOSE_AE
Weight B-OSE_Labeled_AE
Gain I-OSE_Labeled_AE
12 O
% O
2 O
% O
Peripheral B-OSE_Labeled_AE
Edema I-OSE_Labeled_AE
2 O
% O
1 O
% O
Edema B-OSE_Labeled_AE
1 O
% O
0 O
% O
Musculoskeletal B-NonOSE_AE
System I-NonOSE_AE
Myalgia B-OSE_Labeled_AE
2 O
% O
1 O
% O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Somnolence B-OSE_Labeled_AE
54 O
% O
18 O
% O
Dizziness B-OSE_Labeled_AE
7 O
% O
3 O
% O
Abnormal B-OSE_Labeled_AE
Dreams I-OSE_Labeled_AE
4 O
% O
1 O
% O
Thinking B-OSE_Labeled_AE
Abnormal I-OSE_Labeled_AE
3 O
% O
1 O
% O
Tremor B-OSE_Labeled_AE
2 O
% O
1 O
% O
Confusion B-OSE_Labeled_AE
2 O
% O
0 O
% O
Respiratory B-NonOSE_AE
System I-NonOSE_AE
Dyspnea B-OSE_Labeled_AE
1 O
% O
0 O
% O
Urogenital B-NonOSE_AE
System I-NonOSE_AE
Urinary B-OSE_Labeled_AE
Frequency I-OSE_Labeled_AE
2 O
% O
1 O
% O
ECG B-OSE_Labeled_AE
Changes I-OSE_Labeled_AE
The O
electrocardiograms O
for O
338 O
patients O
who O
received O
REMERON O
( O
mirtazapine O
) O
Tablets O
and O
261 O
patients O
who O
received O
placebo O
in O
6-week O
, O
placebo-controlled O
trials O
were O
analyzed O
. O

Prolongation B-NonOSE_AE
in I-NonOSE_AE
QTc I-NonOSE_AE
> I-NonOSE_AE
= I-NonOSE_AE
5 I-NonOSE_AE
0 I-NonOSE_AE
0 I-NonOSE_AE
msec I-NonOSE_AE
was O
not O
observed O
among O
mirtazapine-treated O
patients O
; O
mean B-OSE_Labeled_AE
change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
QTc I-OSE_Labeled_AE
was O
+1.6 O
msec O
for O
mirtazapine O
and O
-3.1 O
msec O
for O
placebo O
. O

Mirtazapine O
was O
associated O
with O
a O
mean O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
heart I-OSE_Labeled_AE
rate I-OSE_Labeled_AE
of O
3.4 O
bpm O
, O
compared O
to O
0.8 O
bpm O
for O
placebo O
. O

The O
clinical O
significance O
of O
these O
changes O
is O
unknown O
. O

The O
effect O
of O
REMERON O
( O
mirtazapine O
) O
on O
QTc O
interval O
was O
assessed O
in O
a O
clinical O
randomized O
trial O
with O
placebo O
and O
positive O
( O
moxifloxacin O
) O
controls O
involving O
54 O
healthy O
volunteers O
using O
exposure O
response O
analysis O
. O

This O
trial O
showed O
a O
positive O
relationship O
between O
mirtazapine O
concentrations O
and O
prolongation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
the I-OSE_Labeled_AE
QTc I-OSE_Labeled_AE
interval I-OSE_Labeled_AE
. O

However O
, O
the O
degree O
of O
QT B-NonOSE_AE
prolongation I-NonOSE_AE
observed O
with O
both O
45 O
mg O
( O
therapeutic O
) O
and O
75 O
mg O
( O
supratherapeutic O
) O
doses O
of O
mirtazapine O
was O
not O
at O
a O
level O
generally O
considered O
to O
be O
clinically O
meaningful O
. O

Other O
Adverse O
Events O
Observed O
During O
the O
Premarketing O
Evaluation O
of O
REMERON O
During O
its O
premarketing O
assessment O
, O
multiple O
doses O
of O
REMERON O
( O
mirtazapine O
) O
Tablets O
were O
administered O
to O
2796 O
patients O
in O
clinical O
studies O
. O

The O
conditions O
and O
duration O
of O
exposure O
to O
mirtazapine O
varied O
greatly O
, O
and O
included O
( O
in O
overlapping O
categories O
) O
open O
and O
double-blind O
studies O
, O
uncontrolled O
and O
controlled O
studies O
, O
inpatient O
and O
outpatient O
studies O
, O
fixed-dose O
and O
titration O
studies O
. O

Untoward O
events O
associated O
with O
this O
exposure O
were O
recorded O
by O
clinical O
investigators O
using O
terminology O
of O
their O
own O
choosing O
. O

Consequently O
, O
it O
is O
not O
possible O
to O
provide O
a O
meaningful O
estimate O
of O
the O
proportion O
of O
individuals O
experiencing O
adverse O
events O
without O
first O
grouping O
similar O
types O
of O
untoward O
events O
into O
a O
smaller O
number O
of O
standardized O
event O
categories O
. O

In O
the O
tabulations O
that O
follow O
, O
reported O
adverse O
events O
were O
classified O
using O
a O
standard O
COSTART-based O
dictionary O
terminology O
. O

The O
frequencies O
presented O
, O
therefore O
, O
represent O
the O
proportion O
of O
the O
2796 O
patients O
exposed O
to O
multiple O
doses O
of O
REMERON O
who O
experienced O
an O
event O
of O
the O
type O
cited O
on O
at O
least O
1 O
occasion O
while O
receiving O
REMERON O
. O

All O
reported O
events O
are O
included O
except O
those O
already O
listed O
in O
Table O
4 O
, O
those O
adverse O
experiences O
subsumed O
under O
COSTART O
terms O
that O
are O
either O
overly O
general O
or O
excessively O
specific O
so O
as O
to O
be O
uninformative O
, O
and O
those O
events O
for O
which O
a O
drug O
cause O
was O
very O
remote O
. O

It O
is O
important O
to O
emphasize O
that O
, O
although O
the O
events O
reported O
occurred O
during O
treatment O
with O
REMERON O
, O
they O
were O
not O
necessarily O
caused O
by O
it O
. O

Events O
are O
further O
categorized O
by O
body O
system O
and O
listed O
in O
order O
of O
decreasing O
frequency O
according O
to O
the O
following O
definitions O
: O
frequent O
adverse O
events O
are O
those O
occurring O
on O
1 O
or O
more O
occasions O
in O
at O
least O
1/100 O
patients O
; O
infrequent O
adverse O
events O
are O
those O
occurring O
in O
1/100 O
to O
1/1000 O
patients O
; O
rare O
events O
are O
those O
occurring O
in O
fewer O
than O
1/1000 O
patients O
. O

Only O
those O
events O
not O
already O
listed O
in O
Table O
4 O
appear O
in O
this O
listing O
. O

Events O
of O
major O
clinical O
importance O
are O
also O
described O
in O
the O
WARNINGS O
and O
PRECAUTIONS O
sections O
. O

Body B-NonOSE_AE
as I-NonOSE_AE
a I-NonOSE_AE
Whole I-NonOSE_AE
: O
frequent O
: O
malaise B-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
acute I-OSE_Labeled_AE
; O
infrequent O
: O
chills B-OSE_Labeled_AE
, O
fever B-OSE_Labeled_AE
, O
face B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
ulcer B-OSE_Labeled_AE
, O
photosensitivity B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
neck B-OSE_Labeled_AE
rigidity I-OSE_Labeled_AE
, O
neck B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
abdomen B-OSE_Labeled_AE
enlarged I-OSE_Labeled_AE
; O
rare O
: O
cellulitis B-OSE_Labeled_AE
, O
chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
substernal I-OSE_Labeled_AE
. O

Cardiovascular B-NonOSE_AE
System I-NonOSE_AE
: O
frequent O
: O
hypertension B-OSE_Labeled_AE
, O
vasodilatation B-OSE_Labeled_AE
; O
infrequent O
: O
angina B-OSE_Labeled_AE
pectoris I-OSE_Labeled_AE
, O
myocardial B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
, O
bradycardia B-OSE_Labeled_AE
, O
ventricular B-OSE_Labeled_AE
extrasystoles I-OSE_Labeled_AE
, O
syncope B-OSE_Labeled_AE
, O
migraine B-OSE_Labeled_AE
, O
hypotension B-OSE_Labeled_AE
; O
rare O
: O
atrial B-OSE_Labeled_AE
arrhythmia I-OSE_Labeled_AE
, O
bigeminy B-OSE_Labeled_AE
, O
vascular B-OSE_Labeled_AE
headache I-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
embolus I-OSE_Labeled_AE
, O
cerebral B-OSE_Labeled_AE
ischemia I-OSE_Labeled_AE
, O
cardiomegaly B-OSE_Labeled_AE
, O
phlebitis B-OSE_Labeled_AE
, O
left B-OSE_Labeled_AE
heart I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
. O

Digestive B-NonOSE_AE
System I-NonOSE_AE
: O
frequent O
: O
vomiting B-OSE_Labeled_AE
, O
anorexia B-OSE_Labeled_AE
; O
infrequent O
: O
eructation B-OSE_Labeled_AE
, O
glossitis B-OSE_Labeled_AE
, O
cholecystitis B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
and O
vomiting B-OSE_Labeled_AE
, O
gum B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
stomatitis B-OSE_Labeled_AE
, O
colitis B-OSE_Labeled_AE
, O
liver B-OSE_Labeled_AE
function I-OSE_Labeled_AE
tests I-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
; O
rare O
: O
tongue B-OSE_Labeled_AE
discoloration I-OSE_Labeled_AE
, O
ulcerative B-OSE_Labeled_AE
stomatitis I-OSE_Labeled_AE
, O
salivary B-OSE_Labeled_AE
gland I-OSE_Labeled_AE
enlargement I-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
salivation I-OSE_Labeled_AE
, O
intestinal B-OSE_Labeled_AE
obstruction I-OSE_Labeled_AE
, O
pancreatitis B-OSE_Labeled_AE
, O
aphthous B-OSE_Labeled_AE
stomatitis I-OSE_Labeled_AE
, O
cirrhosis B-OSE_Labeled_AE
of O
liver O
, O
gastritis B-OSE_Labeled_AE
, O
gastroenteritis B-OSE_Labeled_AE
, O
oral B-OSE_Labeled_AE
moniliasis I-OSE_Labeled_AE
, O
tongue B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
. O

Endocrine B-NonOSE_AE
System I-NonOSE_AE
: O
rare O
: O
goiter B-OSE_Labeled_AE
, O
hypothyroidism B-OSE_Labeled_AE
. O

Hemic B-NonOSE_AE
and I-NonOSE_AE
Lymphatic I-NonOSE_AE
System I-NonOSE_AE
: O
rare O
: O
lymphadenopathy B-OSE_Labeled_AE
, O
leukopenia B-OSE_Labeled_AE
, O
petechia B-OSE_Labeled_AE
, O
anemia B-OSE_Labeled_AE
, O
thrombocytopenia B-OSE_Labeled_AE
, O
lymphocytosis B-OSE_Labeled_AE
, O
pancytopenia B-OSE_Labeled_AE
. O

Metabolic B-NonOSE_AE
and I-NonOSE_AE
Nutritional I-NonOSE_AE
Disorders I-NonOSE_AE
: O
frequent O
: O
thirst B-OSE_Labeled_AE
; O
infrequent O
: O
dehydration B-OSE_Labeled_AE
, O
weight B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
; O
rare O
: O
gout B-OSE_Labeled_AE
, O
SGOT B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
healing B-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
, O
acid B-OSE_Labeled_AE
phosphatase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
SGPT B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
diabetes B-OSE_Labeled_AE
mellitus I-OSE_Labeled_AE
, O
hyponatremia B-OSE_Labeled_AE
. O

Musculoskeletal B-NonOSE_AE
System I-NonOSE_AE
: O
frequent O
: O
myasthenia B-OSE_Labeled_AE
, O
arthralgia B-OSE_Labeled_AE
; O
infrequent O
: O
arthritis B-OSE_Labeled_AE
, O
tenosynovitis B-OSE_Labeled_AE
; O
rare O
: O
pathologic B-OSE_Labeled_AE
fracture I-OSE_Labeled_AE
, O
osteoporosis B-OSE_Labeled_AE
fracture I-OSE_Labeled_AE
, O
bone B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
myositis B-OSE_Labeled_AE
, O
tendon B-OSE_Labeled_AE
rupture I-OSE_Labeled_AE
, O
arthrosis B-OSE_Labeled_AE
, O
bursitis B-OSE_Labeled_AE
. O

Nervous B-NonOSE_AE
System I-NonOSE_AE
: O
frequent O
: O
hypesthesia B-OSE_Labeled_AE
, O
apathy B-OSE_Labeled_AE
, O
depression B-OSE_Labeled_AE
, O
hypokinesia B-OSE_Labeled_AE
, O
vertigo B-OSE_Labeled_AE
, O
twitching B-OSE_Labeled_AE
, O
agitation B-OSE_Labeled_AE
, O
anxiety B-OSE_Labeled_AE
, O
amnesia B-OSE_Labeled_AE
, O
hyperkinesia B-OSE_Labeled_AE
, O
paresthesia B-OSE_Labeled_AE
; O
infrequent O
: O
ataxia B-OSE_Labeled_AE
, O
delirium B-OSE_Labeled_AE
, O
delusions B-OSE_Labeled_AE
, O
depersonalization B-OSE_Labeled_AE
, O
dyskinesia B-OSE_Labeled_AE
, O
extrapyramidal B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
libido B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
coordination B-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
, O
dysarthria B-OSE_Labeled_AE
, O
hallucinations B-OSE_Labeled_AE
, O
manic B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
neurosis B-OSE_Labeled_AE
, O
dystonia B-OSE_Labeled_AE
, O
hostility B-OSE_Labeled_AE
, O
reflexes B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
emotional B-OSE_Labeled_AE
lability I-OSE_Labeled_AE
, O
euphoria B-OSE_Labeled_AE
, O
paranoid B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
; O
rare O
: O
aphasia B-OSE_Labeled_AE
, O
nystagmus B-OSE_Labeled_AE
, O
akathisia B-OSE_Labeled_AE
( O
psychomotor B-OSE_Labeled_AE
restlessness I-OSE_Labeled_AE
) O
, O
stupor B-OSE_Labeled_AE
, O
dementia B-OSE_Labeled_AE
, O
diplopia B-OSE_Labeled_AE
, O
drug B-OSE_Labeled_AE
dependence I-OSE_Labeled_AE
, O
paralysis B-OSE_Labeled_AE
, O
grand B-OSE_Labeled_AE
mal I-OSE_Labeled_AE
convulsion I-OSE_Labeled_AE
, O
hypotonia B-OSE_Labeled_AE
, O
myoclonus B-OSE_Labeled_AE
, O
psychotic B-OSE_Labeled_AE
depression I-OSE_Labeled_AE
, O
withdrawal B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
serotonin B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
. O

Respiratory B-NonOSE_AE
System I-NonOSE_AE
: O
frequent O
: O
cough B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
sinusitis B-OSE_Labeled_AE
; O
infrequent O
: O
epistaxis B-OSE_Labeled_AE
, O
bronchitis B-OSE_Labeled_AE
, O
asthma B-OSE_Labeled_AE
, O
pneumonia B-OSE_Labeled_AE
; O
rare O
: O
asphyxia B-OSE_Labeled_AE
, O
laryngitis B-OSE_Labeled_AE
, O
pneumothorax B-OSE_Labeled_AE
, O
hiccup B-OSE_Labeled_AE
. O

Skin B-NonOSE_AE
and I-NonOSE_AE
Appendages I-NonOSE_AE
: O
frequent O
: O
pruritus B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
; O
infrequent O
: O
acne B-OSE_Labeled_AE
, O
exfoliative B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
, O
dry B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
, O
herpes B-OSE_Labeled_AE
simplex I-OSE_Labeled_AE
, O
alopecia B-OSE_Labeled_AE
; O
rare O
: O
urticaria B-OSE_Labeled_AE
, O
herpes B-OSE_Labeled_AE
zoster I-OSE_Labeled_AE
, O
skin B-OSE_Labeled_AE
hypertrophy I-OSE_Labeled_AE
, O
seborrhea B-OSE_Labeled_AE
, O
skin B-OSE_Labeled_AE
ulcer I-OSE_Labeled_AE
. O

Special B-NonOSE_AE
Senses I-NonOSE_AE
: O
infrequent O
: O
eye B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
abnormality B-OSE_Labeled_AE
of I-OSE_Labeled_AE
accommodation I-OSE_Labeled_AE
, O
conjunctivitis B-OSE_Labeled_AE
, O
deafness B-OSE_Labeled_AE
, O
keratoconjunctivitis B-OSE_Labeled_AE
, O
lacrimation B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
angle B-OSE_Labeled_AE
- I-OSE_Labeled_AE
closure I-OSE_Labeled_AE
glaucoma I-OSE_Labeled_AE
, O
hyperacusis B-OSE_Labeled_AE
, O
ear B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
; O
rare O
: O
blepharitis B-OSE_Labeled_AE
, O
partial B-OSE_Labeled_AE
transitory I-OSE_Labeled_AE
deafness I-OSE_Labeled_AE
, O
otitis B-OSE_Labeled_AE
media I-OSE_Labeled_AE
, O
taste B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
, O
parosmia B-OSE_Labeled_AE
. O

Urogenital B-NonOSE_AE
System I-NonOSE_AE
: O
frequent O
: O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
; O
infrequent O
: O
kidney B-OSE_Labeled_AE
calculus I-OSE_Labeled_AE
, O
cystitis B-OSE_Labeled_AE
, O
dysuria B-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
incontinence I-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
retention I-OSE_Labeled_AE
, O
vaginitis B-OSE_Labeled_AE
, O
hematuria B-OSE_Labeled_AE
, O
breast B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
amenorrhea B-OSE_Labeled_AE
, O
dysmenorrhea B-OSE_Labeled_AE
, O
leukorrhea B-OSE_Labeled_AE
, O
impotence B-OSE_Labeled_AE
; O
rare O
: O
polyuria B-OSE_Labeled_AE
, O
urethritis B-OSE_Labeled_AE
, O
metrorrhagia B-OSE_Labeled_AE
, O
menorrhagia B-OSE_Labeled_AE
, O
abnormal B-OSE_Labeled_AE
ejaculation I-OSE_Labeled_AE
, O
breast B-OSE_Labeled_AE
engorgement I-OSE_Labeled_AE
, O
breast B-OSE_Labeled_AE
enlargement I-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
urgency I-OSE_Labeled_AE
. O

Other O
Adverse O
Events O
Observed O
During O
Postmarketing O
Evaluation O
of O
REMERON O
Adverse O
events O
reported O
since O
market O
introduction O
, O
which O
were O
temporally O
( O
but O
not O
necessarily O
causally O
) O
related O
to O
mirtazapine O
therapy O
, O
include O
cases O
of O
the O
ventricular B-OSE_Labeled_AE
arrhythmia I-OSE_Labeled_AE
Torsades B-OSE_Labeled_AE
de I-OSE_Labeled_AE
Pointes I-OSE_Labeled_AE
. O

In O
the O
majority O
of O
these O
cases O
, O
however O
, O
concomitant O
drugs O
were O
implicated O
. O

Cases O
of O
severe O
skin B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
including O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
bullous B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
, O
erythema B-OSE_Labeled_AE
multiforme I-OSE_Labeled_AE
and O
toxic B-OSE_Labeled_AE
epidermal I-OSE_Labeled_AE
necrolysis I-OSE_Labeled_AE
have O
also O
been O
reported O
. O

Increased B-OSE_Labeled_AE
creatine I-OSE_Labeled_AE
kinase I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
and O
rhabdomyolysis B-OSE_Labeled_AE
have O
also O
been O
reported O
. O

